Boston Scientific Corporation $BSX Holdings Decreased by Tocqueville Asset Management L.P.

Tocqueville Asset Management L.P. cut its position in shares of Boston Scientific Corporation (NYSE:BSX) by 6.0% during the 3rd quarter, HoldingsChannel.com reports. The firm owned 446,729 shares of the medical equipment provider’s stock after selling 28,466 shares during the period. Tocqueville Asset Management L.P.’s holdings in Boston Scientific were worth $43,614,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other hedge funds have also recently added to or reduced their stakes in the business. Norges Bank bought a new stake in Boston Scientific during the second quarter valued at $2,089,937,000. Edgewood Management LLC bought a new position in shares of Boston Scientific in the 2nd quarter worth about $746,655,000. Parnassus Investments LLC boosted its holdings in shares of Boston Scientific by 42,978.9% in the 3rd quarter. Parnassus Investments LLC now owns 6,884,440 shares of the medical equipment provider’s stock valued at $672,128,000 after buying an additional 6,868,459 shares during the period. Egerton Capital UK LLP grew its position in shares of Boston Scientific by 223.7% during the 3rd quarter. Egerton Capital UK LLP now owns 5,312,504 shares of the medical equipment provider’s stock valued at $518,660,000 after buying an additional 3,671,548 shares during the last quarter. Finally, Jennison Associates LLC grew its position in shares of Boston Scientific by 133.5% during the 3rd quarter. Jennison Associates LLC now owns 4,938,746 shares of the medical equipment provider’s stock valued at $482,170,000 after buying an additional 2,823,744 shares during the last quarter. Institutional investors and hedge funds own 89.07% of the company’s stock.

Insider Transactions at Boston Scientific

In related news, CEO Michael F. Mahoney sold 160,901 shares of the stock in a transaction that occurred on Monday, February 2nd. The stock was sold at an average price of $93.49, for a total value of $15,042,634.49. Following the completion of the transaction, the chief executive officer directly owned 1,411,735 shares of the company’s stock, valued at $131,983,105.15. This represents a 10.23% decrease in their position. The sale was disclosed in a filing with the SEC, which is available through the SEC website. 0.50% of the stock is owned by company insiders.

Wall Street Analyst Weigh In

A number of equities analysts have issued reports on the stock. UBS Group cut their target price on shares of Boston Scientific from $140.00 to $120.00 and set a “buy” rating on the stock in a report on Thursday, February 5th. Wells Fargo & Company lowered their target price on Boston Scientific from $125.00 to $94.00 and set an “overweight” rating for the company in a report on Thursday, February 5th. Canaccord Genuity Group dropped their price target on Boston Scientific from $112.00 to $109.00 and set a “buy” rating on the stock in a research report on Tuesday, February 17th. Royal Bank Of Canada cut their price target on Boston Scientific from $130.00 to $115.00 and set an “outperform” rating on the stock in a report on Thursday, February 5th. Finally, Oppenheimer reduced their price objective on Boston Scientific from $125.00 to $100.00 and set an “outperform” rating for the company in a research report on Friday, January 16th. Two equities research analysts have rated the stock with a Strong Buy rating, twenty have assigned a Buy rating and three have assigned a Hold rating to the company. According to MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average target price of $108.00.

Trending Headlines about Boston Scientific

Here are the key news stories impacting Boston Scientific this week:

• Positive Sentiment: Citigroup reduced its price target for BSX from $102 to $94 but kept a “buy” rating, signaling continued analyst confidence in long‑term upside even after trimming near‑term expectations. Citigroup Lowers Boston Scientific Price Target
• Neutral Sentiment: Market commentary notes BSX underperformed the broader market today as investors reacted to both the analyst update and the growing legal headlines — a short-term sentiment move rather than company fundamental news. Why Boston Scientific Dipped Today (Zacks)
• Negative Sentiment: Multiple plaintiff firms allege executives misrepresented U.S. electrophysiology procedure growth; a formal securities class action has been filed covering July 23, 2025–Feb 3, 2026. The allegation of inflated procedure volumes is a direct claim against prior disclosures and is a material legal risk that can pressure the stock until resolved. Lawsuit Alleging Misrepresentation of EP Volumes
• Negative Sentiment: A broad slate of law firms (Rosen, Pomerantz, Glancy Prongay, Robbins Geller, Faruqi, Bernstein Liebhard, Bronstein Gewirtz & Grossman, and others) have issued investor alerts and reminders about lead‑plaintiff deadlines (May 4, 2026), increasing the likelihood of consolidated litigation and ongoing media attention — a persistent headline risk. Shareholder Alert — Gross Law Firm

Boston Scientific Stock Performance

NYSE:BSX traded up $0.15 during mid-day trading on Friday, hitting $68.70. The stock had a trading volume of 1,839,028 shares, compared to its average volume of 15,647,020. The company has a current ratio of 1.62, a quick ratio of 1.08 and a debt-to-equity ratio of 0.46. The company has a 50 day simple moving average of $82.98 and a 200-day simple moving average of $93.64. The stock has a market capitalization of $101.94 billion, a price-to-earnings ratio of 35.34, a P/E/G ratio of 0.97 and a beta of 0.69. Boston Scientific Corporation has a 52 week low of $67.56 and a 52 week high of $109.50.

Boston Scientific (NYSE:BSX) last posted its earnings results on Wednesday, February 4th. The medical equipment provider reported $0.80 EPS for the quarter, topping the consensus estimate of $0.78 by $0.02. The firm had revenue of $5.29 billion during the quarter, compared to analysts’ expectations of $5.29 billion. Boston Scientific had a net margin of 14.44% and a return on equity of 19.63%. Boston Scientific’s quarterly revenue was up 15.9% on a year-over-year basis. During the same quarter in the prior year, the firm earned $0.70 EPS. Boston Scientific has set its Q1 2026 guidance at 0.780-0.800 EPS and its FY 2026 guidance at 3.430-3.490 EPS. On average, research analysts expect that Boston Scientific Corporation will post 2.85 earnings per share for the current fiscal year.

Boston Scientific Company Profile

Boston Scientific Corporation (NYSE: BSX) is a global medical device company that develops, manufactures and markets a broad portfolio of products used in less-invasive medical procedures. Founded in 1979 by John Abele and Peter Nicholas, the company is headquartered in Marlborough, Massachusetts, and focuses on technologies that enable physicians to treat a wide range of cardiovascular, digestive, urologic, pulmonary and chronic pain conditions without open surgery.

Boston Scientific’s activities span product development, clinical research, regulatory affairs and commercial sales.